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Abstract
Background: Patients with bipolar disorder (BD) suffer from cognitive deficits across several domains. The association between 
cognitive performance and psychosocial functioning has led to the emergence of cognition as a treatment target.A
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Objective: This study reviews the existing literature on cognitive enhancement interventions for people with BD, focusing on 
different treatment approaches and methodological quality. 
Methods: We conducted a systematic search following the PRISMA guidelines. Sample characteristics and main outcomes for each 
study and treatment characteristics for each approach were extracted. Study quality was assessed using the Clinical Trials 
Assessment Measure (CTAM) and Cochrane Collaboration’s Risk of Bias tool by independent raters.    
Results: Eleven articles reporting data from seven original studies were identified encompassing 471 participants. Two treatment 
approaches were identified, cognitive and functional remediation. For controlled studies, methodological quality was modest 
(average CTAM score = 60.3), while the overall risk of bias was considered moderate. Beneficial effects on cognitive or functional 
outcomes were reported in the majority of studies (91%), but these findings were isolated and not replicated across studies. Key 
methodological limitations included small sample sizes, poor description of randomization process, high attrition rates, and 
participant exclusion from the analysis. 
Conclusions: Findings are promising but preliminary. Quality studies were few and mostly underpowered. Heterogeneity in sample 
characteristics, outcome measures, and treatment approaches further limit the ability to generalize findings. Adequately powered 
trials are required to replicate initial findings, while moderators of treatment response and mechanisms of transfer need to be 
explored.  
Keywords: bipolar disorder, cognition, functioning, cognitive remediation, functional remediation, methodological quality. 
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1. Introduction
Cognitive dysfunction is common in people with bipolar disorder (BD) and presents a profile qualitatively similar to that of people 
with schizophrenia, but less severe overall (1, 2). Impairment occurs in several cognitive domains with relevant meta-analyses 
reporting moderate to large deficits in attention, verbal learning and memory, and executive function (3, 4). These deficits are 
more pronounced during mood episodes but do persist and remain clinically significant after symptom remission and during 
euthymia (3, 5). What remains unclear is the relationship between illness progression and cognitive dysfunction for people with 
BD. Impairments may reflect neurodevelopmental factors, such as genetic susceptibility, and illness progression, such as the 
neurotoxic effects of recurrent mood episodes as well as chronic medication use (6). However, according to recent evidence only 
40% of people with BD present significant deficits across multiple cognitive domains while another subgroup (30%) shows 
selective moderate impairments and the rest remain cognitively intact (7, 8). This heterogeneity poses serious methodological and 
clinical challenges when assessing the efficacy of interventions targeting cognitive impairment in this group of patients.
Cognitive interventions have emerged as a new treatment option to promote functional recovery of patients with BD. The 
association between cognition and function has been extensively explored, with most evidence suggesting significant 
contributions of cognitive impairment to reduced functional capacities (9, 10). Cognitive measures have been found to predict 
psychosocial functioning independently to residual depressive symptoms (11). Importantly, recent evidence from a large meta-
analysis showed that cognitive performance, particularly verbal memory and executive function, is one of the strongest predictors 
of favourable employment outcomes (12). Despite this evidence, there is limited research on cognitive enhancement 
interventions for people with BD. For pro-cognitive pharmacological treatments, only preliminary evidence is reported from trials 
with severe methodological limitations (13). Findings on psychological treatments targeting cognitive impairment, such as 
cognitive remediation (CR), were also limited until recently. CR is a well-established intervention tackling cognitive and functional 
difficulties in people with schizophrenia, but CR approaches for people with BD have only emerged over the past few years (14). A 
meta-analysis using only the subgroups of participants with affective diagnoses from mixed sample studies shows that CR may 
have comparable benefits on cognition in affective and schizoaffective disorders as in schizophrenia (15). Subsequent studies have 
further explored the effects of CR and other interventions on cognitive and functional outcomes in people with BD.          A
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The current report aims to review the evidence from studies examining cognitive enhancement interventions for people with BD 
in a systematic way. Tackling cognitive and functional difficulties is a new research field in BD. To consolidate a wider evaluation of 
its current status this review will emphasize two further aspects: a comparison of the intervention approaches assessed in people 
with BD and the methodological quality of the available studies. We believe that a critical reflection on the existing evidence 
quality will further appraise the reported efficacy of these interventions. Similarly, a comprehensive comparison of different 
treatment approaches targeting cognitive dysfunction may elucidate the clinical implications of previous findings and provide 
useful directions for improving future research in the field.
2. Methods
This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
guidelines (PRISMA) (16). A protocol of the review was registered with the online database PROSPERO (registration number: 
CRD42018092130). 
2.1 Data sources and search strategy
Systematic searches from the first available date to March 2019 were conducted in the following electronic databases: MEDLINE 
(PubMed), Embase, PsycINFO, Web of Science, and the Cochrane Collaboration Controlled Trials Register. The following search 
terms were used as keywords for the searches: (bipolar OR bd OR bpad OR manic-depress* OR manic depress*) AND (cognit* OR 
neurocognit* OR neuropsycholog*) AND (remediation OR rehabilitation OR training OR enhancement OR therapy). To identify any 
additional reports potentially missed, the reference lists of included studies, previous relevant reviews, and notable articles in the 
area were inspected. 
2.2 Eligibility criteria
The following inclusion and exclusion criteria were used: 
Participants: We considered studies involving adult participants (aged between 18-65) with a BD diagnosis according to the 
Diagnostic and Statistical Manual of Mental Disorders (17), the International Classification of Diseases (18), or the Research 
Diagnostic Criteria (19). Studies with mixed samples were only considered if participants with BD represented 40% or more of the 
sample.   
Interventions: All interventions targeting any cognitive and/or any functional outcomes were considered. We also considered the 
combination of cognitive enhancement with other interventions (e.g., social cognitive training) if the cognitive training was a 
significant therapy component and accounted for a significant proportion of the therapy time (i.e., ≥ 40%). 
Comparators: Eligible comparators included other active treatments not primarily targeting cognitive difficulties (e.g., 
psychoeducation, group support etc.), treatment-as-usual (TAU), or waiting list.  
Outcomes: Only studies employing validated measures were considered. A
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Study design: All relevant studies were considered including randomized and quasi-randomized controlled trials, feasibility or pilot 
studies, and uncontrolled designs. We also considered sub-analyses and follow-up analyses reported in different manuscripts than 
the original study. Randomized controlled trials (RCTs) were prioritized in data synthesis and interpretation of the evidence.
2.3 Study selection
First the titles and then the abstracts of identified studies were screened by two authors independently (DT, BS). Full text reports 
were retrieved for all the articles considered eligible based on the first screening and were further reviewed for inclusion (DT, BS). 
Disagreements on the included studies were resolved based on consensus between the reviewers and, if required, after discussion 
with a third senior author (MC or TW). 
2.4 Data extraction and synthesis
Two authors (DT, TM) independently extracted the following data from each article to collate relevant and comparable 
information from different reports: first author and year of publication, sample size and number of participants with BD, study 
design, demographic (age, gender, education) and clinical characteristics (premorbid IQ, BD type, illness duration, number of 
episodes, hospitalizations, current mood), type of intervention and control, assessment time-points and outcome measures, main 
findings, discontinuation rates, adverse events, and limitations. The following characteristics were extracted for each treatment 
approach: type and delivery method, setting, duration, main targets and core therapy components. Treatment outcomes are 
presented in a narrative synthesis, grouped by intervention type to enable comparisons and facilitate evidence interpretation. 
2.5 Quality assessment and risk of bias
Methodological quality of controlled trials was assessed using the Clinical Trials Assessment Measure (CTAM) (20, 21). This is a 15-
item scale assessing the methodology of studies examining psychological treatments. The features assessed by the CTAM include: 
sample characteristics, treatment allocation, comparators, assessment of outcome measures, active treatment description, and 
analysis, with quality ratings ranging between 0 and 100. Two reviewers (DT, TM) independently evaluated each report and any 
rating discrepancies were resolved by a senior author (MC). To ensure the accuracy of the ratings, and to avoid confusion between 
conduct quality and reporting quality, all corresponding authors were contacted and asked to examine the accuracy of our ratings. 
If necessary, amendments were made according to their feedback. The risk of bias for RCTs was also evaluated by two reviewers 
(DT, TM) using the Cochrane Collaboration’s Risk of Bias tool (22). 
3. Results
3.1 Study characteristics
The search and selection process are described in the PRISMA flowchart (Figure 1). Eleven articles reporting data from seven 
original studies were included in the review, assessing a total number of 471 participants: three were RCTs, two were non-A
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randomized controlled trials, and two were uncontrolled studies. All seven original studies were conducted by independent 
research groups and included unique sample sizes. The remaining four reports were follow-up or secondary analyses of the same 
RCT.
--- Figure 1 here ---
Three studies were conducted in the USA, and the remaining four in Europe. Sample sizes varied greatly, ranging from 12 to 239 
participants and with a mean of 67. Participants across studies were primarily women (57%) and had an average age of 38.2 years. 
Five studies reported education attendance (13.4 years) and another five estimates of premorbid IQ (108.7). Most participants 
had a diagnosis of BD type I (64.7%) and an average illness duration of 14.7 years (range: 7-28). Participants had experienced 8.9 
mood episodes and had been admitted to the hospital 2.9 times on average. All studies recruited outpatients. Table 1 displays the 
characteristics of all included reports. 
--- Table 1 here ---
3.2 Intervention characteristics
The main characteristics and aims for each intervention are described in Table 2. Other than traditional CR approaches, a novel 
remediation approach for people with BD was identified, functional remediation (FR). Out of the seven original studies, five 
investigated CR and six FR approaches. None were combined with another active treatment. Of the controlled studies, three used 
treatment-as-usual (TAU) as a comparator, one CR trial used computer games as an active control condition, and five FR reports 
had both TAU and an active intervention (i.e., psychoeducation).  
Most studies (63%) delivered therapy through pen-and-paper activities; the remaining used various types of computer software. 
In terms of setting, three interventions were delivered individually, while the rest employed a group or a combination format with 
small group sizes (4-8 participants) and one or more group facilitators. One study also invited caregivers to attend 
psychoeducational group sessions. Therapy duration varied from 12 to 24 weeks with an average of 16.2 weeks. The target for 
treatment sessions ranged from 12 to 70 and had an average of 23.5, but most interventions supplemented group or individual 
sessions with learning materials about BD and homework exercises or tasks. However, only two CR programmes delivered highly 
intensive training with multiple sessions weekly. These were the only ones not using a therapist to support or guide participants 
during their cognitive training (23, 24).A
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CR and FR approaches presented a similar adherence profile. Mean treatment discontinuation rates were 28.7% for CR and 28.6% 
for FR. The main reasons for discontinuing therapy were workload and time requirements, lack of motivation to engage with the 
therapy, and changes in mental health status. CR satisfaction was assessed only in one trial where participants in the active 
therapy group reported moderate-to-high ratings using a feedback survey (23). Satisfaction for FR was examined only by an 
uncontrolled study with participants highly rating group and individual sessions (25). CR and FR were tolerated well: adverse 
events were scarce and equally balanced between active and control groups. Exacerbation of affective symptoms was reported 
from 19 participants across five studies, with 10 receiving an active therapy and nine the control condition.   
--- Table 2 here ---
                
3.3 Methodological quality
Table 3a displays the CTAM ratings for the included controlled studies. The mean CTAM score was 60.3 (SD 15.1) with a range of 
29 to 74. All corresponding authors were contacted, and three replied with their feedback: two agreed with our initial rating and 
one suggested an amendment. The total CTAM increase was only three points. Only four studies (44%) had a score above the cut-
off of 65 (21), indicating low susceptibility to bias. The primary problem was low sample sizes (44%), unblinded assessments (77%), 
not applying intention-to-treat (ITT) analysis (66%), lack of treatment protocols (33%) and fidelity assessments (100%). Most 
studies did allocate participants randomly (78%), but this randomization process was commonly not independent to the study 
team (88%). Another problem was high attrition rates which ranged from 12.8% to 38.4% (mean: 26.6%) for active treatment 
groups and from 4.3% to 30.5% (mean: 17.1%) for control groups. Only one study reported an overall drop-out rate lower than 
15%.     
Table 3b shows the risk of bias ratings for included RCTs and RCT sub-analyses. The overall risk of bias was considered moderate 
according to the Cochrane tool which corresponds with the mean CTAM rating for the included reports. 
--- Tables 3a and 3b here ---
3.4 Intervention outcomes
The largest CR trial to date (N=75) reported significant improvement for the treatment group in a global cognition score (Cohen’s 
d=0.8), as well as moderate-to-large effects in visual-spatial learning (Cohen’s d=0.92) and processing speed (Cohen’s d=0.65) (23). A
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Though cognitive improvement was correlated with changes in the primary functional outcome across the sample, a significant CR 
effect over computer control was not detected for community functioning. An earlier smaller trial (N=46) showed no beneficial 
effects of CR over standard treatment on verbal memory or any other secondary outcomes (26). CR was only associated with 
improvements in verbal fluency (Cohen’s d=0.25) and quality of life (Cohen’s d=0.75) at the 6-month follow-up. Two non-
randomized studies have presented moderate effects of CR on cognitive outcomes over control conditions. Preiss et al. (24) 
delivered computerized CR to 15 depressed outpatients with unipolar or bipolar disorder and reported post-treatment reduction 
in attentional and executive difficulties compared to 16 age- and diagnosis-matched controls. In a study where participants were 
self-selected for CR or TAU, authors reported improvements in problem solving and working memory for the treatment group 
(27). The earliest study to examine CR for people with BD (N=18) reported improvement in an observer-rated measure of 
executive dysfunction, and measures of occupational and psychosocial functioning after 14 CR sessions (28). In total, four out of 
five CR studies (80%) showed significant improvement in one or more cognitive outcomes with effect sizes ranging from small to 
large (0.35-0.95). For functional outcomes, only two studies (40%) reported significant changes at post-treatment or follow-up. 
Although all studies explored the association between cognitive and functional changes, a significant correlation was not detected 
specifically for the CR group in any of those.       
FR was primarily investigated in a large randomized trial (N=239) which allocated participants to FR (N=77), psychoeducation (PE; 
N=82) or TAU (N=80) (29). The post-treatment effect of FR on psychosocial functioning was small-to-moderate versus TAU 
(Cohen’s d=0.3), but a significant difference was not found over the PE group. For cognitive outcomes, no significant benefits were 
reported for FR over PE or TAU. A follow-up analysis one year after baseline (N=172) showed that FR maintained a small effect on 
functioning over TAU (Cohen’s d=0.18), and additionally demonstrated an improvement in verbal memory for the FR group only 
(30). Several post-hoc analyses used data from this original trial to further explore the effect of FR on cognition and functioning. 
Bonnin et al (31) analysed a subgroup of participants presenting objective cognitive impairment (i.e., score of 2 SDs or more below 
the normative mean in one or more measures; N=188) and reported a small effect of FR over TAU in verbal memory (Cohen’s 
d=0.3), while a small effect over control was found for psychosocial functioning (Cohen’s d=0.2). FR was not superior to PE in any 
of these measures. A small sub-analysis of the 53 participants with a bipolar type-II diagnosis did not replicate any of the previous 
effects of FR on cognition or functioning over TAU, showing only a reduction in depressive symptoms (32). However, a larger sub-
analysis considering participants with subthreshold depressive symptoms (N=99) did report a significant functional improvement 
over TAU (Cohen’s d=1.12) and PE (Cohen’s d=0.37) which were maintained at 1-year follow-up (33). No differences were found 
for any of the cognitive measures. Recently, a small uncontrolled study (N=12) described improved psychosocial functioning 
following a brief group FR focused on personalized goals (25). Overall, five out of six FR studies (83.4%) reported significant 
benefits for psychosocial functioning with a moderate mean effect (Cohen’s d=0.45) using the same clinician-rated measure 
(Functional Assessment Short Test [FAST]) (34). Cognitive benefits were only demonstrated for verbal memory in two reports 
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(33.3%) with a small mean effect (Cohen’s d=0.25). A significant association between cognitive and functional changes specifically 
for the FR group was only detected in one study (30).  
The association of methodological quality with treatment outcomes was unclear for the included studies. CTAM scores ranged 
from 29 to 74 for studies reporting significant changes in one or more outcomes. The same range for studies with no significant 
effects was 62 to 70. There was a negative but not significant correlation (Spearman’s r=-0.18) between CTAM scores and effect 
sizes reported for cognitive and functional outcomes. Sample size possibly was a key variable for this relationship: larger studies 
were more rigorous (Spearman’s r=0.74, p=0.24) and associated with reporting smaller effect sizes (Spearman’s r=-0.71, p=0.31).    
4. Discussion
Treating cognitive impairment in people with BD may benefit psychosocial difficulties and improve occupational outcomes (11, 
35). This review evaluated the evidence on cognitive enhancement interventions for people with BD focusing on the different 
treatment paradigms available and the methodological quality of the included studies. Two interventions have been considered 
for people with BD, cognitive and functional remediation. CR approaches were heterogeneous in terms of delivery method, 
therapy components and goals. Methodology varied significantly among the included reports and quality ratings were moderate 
on average. Cognitive enhancement interventions showed positive findings for cognitive and functional outcomes, but these were 
not robust and can only be considered preliminary, which is in line with recent relevant reviews(13, 36, 37).
4.1 Cognitive remediation
CR comprised various treatment approaches with common characteristics but also significant differences. Literature on people 
with schizophrenia has divided CR into two paradigms: restorative and compensatory (38). Restorative approaches have 
emphasized intensive and repetitive training with increasing levels of difficulty (39), while compensatory ones combine cognitive 
training with strategy learning which is considered the key to transfer any cognitive improvement into functional outcomes (40). 
For studies considered in this review, the main differences between restorative and compensatory approaches were the role of 
the therapist and the number of sessions. Therapists adopted more active roles in compensatory CR approaches aiming to 
emphasize strategy use and to bridge individual or group training with daily-life activities (26). For restorative programmes, the 
primary focus was massed computer training with progressively more difficult tasks and multiple sessions per week, while it was 
not clearly reported if any guidance or support was provided by a therapist (23).  
CR was accepted well and was associated with some cognitive improvements in the studies considered. However, evidence was 
inconsistent, with some studies reporting beneficial treatment effects and others no significant changes. This may reflect the 
methodological limitations of most studies, particularly small sample sizes with inadequate power to detect treatment effects. 
Significant variability in the CR approaches (e.g., every study used a different computer software) might have contributed to that. 
Studies recruited samples with different characteristics at baseline which might have affected treatment outcomes. For example, A
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Lewandowski et al. (23) recruited patients with history of psychosis which has been associated with greater cognitive impairments 
and larger potential for improvement (41). 
Overall, results are in line with previous reviews in this population. Anaya et al. (15) conducted a meta-analysis of 18 CR studies 
having a significant proportion of participants with schizo-affective or affective disorders in their sample (N=300; 35%) and 
reported a pooled mean effect size of 0.36 for cognitive outcomes. As in the current review, authors described significant 
methodological limitations such as the uncontrolled design of several studies and the heterogeneity of CR approaches. A more 
recent CR review for patients with affective psychosis reported moderate-to-large effect sizes (Cohen’s d=0.36-0.94), but findings 
were not replicated for most domains across studies (42). Examining the effect of CR on different cognitive domains in the studies 
considered, we found minimal consistency in post-treatment benefits since most significant findings did not replicate. The only 
domain showing improvement in several studies was executive functioning, such as problem solving and set shifting. This is an 
encouraging finding given that impairments in executive functions have been proposed as a cognitive endophenotype of BD (43). 
The scarcity of high quality and adequately powered trials in people with BD limits the comparison to people with schizophrenia 
where a robust body of evidence suggests at least moderate effect sizes (44). Patients with schizophrenia show more pronounced 
cognitive impairment and are more likely to benefit following CR than patients with affective diagnoses since they are less 
susceptible to ceiling effects in cognitive measures (45). This baseline discrepancy might disappear though, if only BD patients with 
a history of psychosis or with objective cognitive impairments are considered. This was supported by a recent meta-regression of 
five RCTs (N=300) examining CR in mixed samples with severe mental illness (SMI) including schizophrenia, schizo-affective and 
affective disorders. Authors confirmed lower baseline cognitive performance is associated with greater response to CR, but this 
was independent of diagnosis type (46). 
To date, there have not been any trials comparing the effects of CR among different diagnostic groups. However, it is worth 
commenting on a significant amount of CR studies identified from our search (n=12) with SMI samples including a percentage of 
patients with BD (N with BD=162; mean proportion: 26%; range: 6-34%). A randomized trial of individual CR combined with group 
discussions described significant improvement in processing speed and verbal memory for the treatment group over 
computerized control (47). Participants in this group were employed at a greater rate compared to control at the 12-month 
follow-up. In a recent RCT with 24% of the sample diagnosed with BD, CR was associated with significant improvement in 
executive functioning, while participants in the treatment group reported better work outcomes over the next two years (48). 
Although none of these studies presented results separately for different diagnostic groups, cognitive and functional 
enhancement were reported for participants across diagnoses.  Thus, diagnosis may be less important to treatment response than 
other individual factors such as objective cognitive difficulties. Finally, mixed sample studies had several methodological 
limitations and examined variable CR approaches, similar to the studies considered in this review.
4.2 Functional remediationA
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FR was developed specifically to address difficulties for people with BD and overlaps greatly with compensatory CR in terms of 
treatment mechanisms. Both approaches attempt to teach adaptive strategies and techniques to overcome cognitive and 
functional difficulties (49). Unlike CR studies, where multiple approaches were examined, all FR studies involved the same therapy 
protocol and all, but one uncontrolled study, were conducted by the same research group. This protocol emphasized education 
about cognitive deficits and their impact on everyday life, as well as training of functional skills using role-playing and real-life 
exercises. Results from these studies suggest greater improvements for FR over TAU in overall psychosocial functioning, which was 
assessed consistently across studies using a recommended measure (FAST). Benefits were particularly demonstrated for the 
domains of autonomy, interpersonal relationships, and occupational functioning. 
Although still not replicated by other studies, results from this group are in line with findings from schizophrenia research. A 
previous meta-analysis considering the effects of CR on functional outcomes reported a moderate mean effect size (Cohen’s 
d=0.42) which was durable over time (44). Benefits for functional outcomes were linked to compensatory remediation 
approaches, like FR, over restorative ones. However, what FR studies have yet to examine is the efficacy on ‘hard’ occupational 
outcomes, such as employment rates and wages over long follow-up periods, which have been reported from similar therapeutic 
approaches in SMI studies (48, 50). For cognitive outcomes, verbal memory was the only domain found to improve following FR, 
and importantly the only domain associated with changes in psychosocial functioning over time (30). Impairment in this domain is 
a strong predictor of psychosocial functioning in BD and any changes would normally affect functional performance (51). 
4.3 Limitations
There were several factors limiting the studies considered in this review.
Methodological quality: The mean CTAM score was 60.3 which is below the threshold of high methodological quality according to 
Wykes et al. (21). This might indicate that treatment effects have been overestimated due to poor methodological quality. 
Previous reviews using this measure have reported comparable mean CTAM scores, 61.2 for trials examining cognitive behavioral 
therapy (CBT) (21) and 57.4 for trials assessing CR interventions (44). The review of CBT detected an association between 
methodological rigor and reported effect sizes, while methodological ratings did not correlate with therapy effects for CR trials. 
Unlike these reviews where a large number of studies were considered, the small number of studies included in our review 
potentially limits the capacity to further explore the relationship between quality ratings and changes in outcome measures. CR 
for people with BD is an emerging research field and most of the studies to date were feasibility or pilot trials which commonly 
involve methodological shortcomings and cannot reliably estimate effect sizes due to small sample sizes. Regarding measure 
selection, most studies did not have a clear a priori defined hierarchy of primary and secondary outcomes. Statistical analysis was 
limited due to the violation of the ITT principle, the lack of imputation methods to appropriately handle missing data (e.g., mixed-
models approach), and the absence of control for multiple testing (e.g., Bonferroni correction). Another limitation was the way 
treatment effect was estimated in some studies which chose to report within-group effect sizes despite including a control A
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condition. Within-group effects can overestimate the impact of an intervention since changes in the control group are not 
considered. 
Heterogeneity: Great variability in sample characteristics, cognitive measures, and treatment approaches was present across 
studies. Only two reports included objective cognitive screening. This led to cognitively heterogeneous study samples since not 
every patient with BD had cognitive deficits (52). Such samples involve the risk of underestimating the efficacy of an intervention 
due to lack of impairments in a significant proportion of the sample and, thus, allowing little room for improvement following 
therapy. Regarding clinical characteristics, not every study recruited participants who were free of acute affective symptoms 
which may have hindered therapy delivery and reliability of cognitive assessments. Mood symptoms can limit the impact of an 
intervention on cognition, while cognitive improvement might be the product of changes in mood outcomes (53). Although most 
studies used objective and validated measures, cognitive performance was examined differently across studies and this limits the 
comparability between findings. Studies adopted a variety of measures to assess individual cognitive domains and did not report 
composite cognitive scores to assess global cognition, with the exception of one trial using the MATRICS Consensus Cognitive 
Battery (MCCB) (54). None of the studies considered in this review used the cognitive battery recommended by the International 
Society for Bipolar Disorders (55). Heterogeneity was also evident in CR approaches, especially in regard to duration and intensity, 
delivery method, and goal setting. These differences may limit the generalization of post-treatment improvements across 
different CR programmes. Variability in the included studies is described in Table 4. 
Durability of outcomes: Most studies in this review included only short follow-up periods, with a mean of 25.5 weeks, while several 
did not conduct assessments after the end of therapy. Hence, it remains unclear if any post-therapy effects are durable over time. 
Another reason longer follow-up periods are required is to examine the association between cognitive and functional change. 
According to Miskowiak et al. (55), there is a time-lag between cognitive changes and improvement in functional competence. 
Trials need to allow follow-up periods of at least three months following therapy completion to explore this association. For 
example, studies with mixed SMI samples examining occupational outcomes after CR involved long follow-up periods, typically 
over one year (47, 48). In people with BD, the only study reporting a significant correlation between improvement in verbal 
memory and functional changes over time was the one with a 12-month follow-up period (30).
--- Table 4 here ---
4.4 Future research directions
An international task force has recently considered a series of methodological challenges for cognition trials in BD such as 
inclusion criteria, selection of outcomes, and statistical issues (55). Experts provided numerous consensus-based 
recommendations for future trials to improve their sensitivity in detecting treatment effects. Recommendations included 
enriching study samples for cognitive impairment by screening potential participants with objective cognitive measures, recruiting 
patients without acute mood symptoms and selecting a composite score as primary cognitive outcomes. Regarding psychological A
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interventions targeting cognition, appropriately designed and rigorous randomized trials are required to address current 
methodological limitations. Future trials should involve larger sample sizes to estimate efficacy of these interventions with 
adequate power, homogeneity in sample characteristics and outcome measures to enable generalisability and comparability of 
findings, and precise statistical analyses to avoid any inflation of treatment effects. Currently, there are some registered trials 
testing different CR approaches in patients with BD (56-58).
Larger trials may allow the exploration of mechanisms and patients’ characteristics associated with treatment response. Factors 
such as age (59), pre-treatment cognitive performance (46), and cognitive reserve (23) are candidate moderators of CR response 
based on theory and some initial evidence from affective populations. The role of these factors in CR for people with BD needs to 
be further explored to improve treatment outcomes. Modern statistical techniques, such as machine learning, can refine the 
search for these underlying treatment mechanisms even in smaller samples (60). Additional moderating factors might include 
illness duration, number of mood episodes, and diagnostic subtype. The role of anxiety symptoms is also worth exploring as some 
evidence indicates an association with CR response for people with BD (28). Identifying response moderators may allow the 
development of personalized CR approaches for people with BD, tailored to the specific difficulties experienced from particular 
patient subgroups and adapted to different cognitive profiles. Recent findings point to distinct cognitive subgroups in terms of 
strengths and deficits in executive functions which might indicate a variability of cognitive phenotypes in BD and potentially 
different therapy requirements (61).       
Another important area is the association between cognitive improvement and changes in psychosocial functioning. Only minimal 
findings have been reported about the translation of cognitive into functional gains in studies including people with BD (30, 62), 
potentially due to the limitations previously discussed. Future trials should examine the long-term benefits in daily life outcomes 
(e.g., work) and the transfer mechanisms connecting therapy with these functional improvements, as previously demonstrated for 
people with schizophrenia (63). In that context, future research should investigate the therapy components mostly associated 
with post-treatment cognitive and functional changes (64) since no indications currently exist of how therapy duration or delivery 
method may affect outcomes in people with BD.           
Similarly, only few of the studies considered in this review explored the satisfaction rates among patients receiving therapy. Taking 
15% as a minimum attrition threshold to ensure validity of the findings (44), both treatment discontinuation and trial drop-out 
were increased across the included studies suggesting low acceptability and showing that refinements are required in therapy 
protocols. In addition, none of the studies examined participant satisfaction in relation to treatment outcomes. Perceiving an 
intervention as beneficial can be critical for the overall treatment effect in the long-term (65). Future trials in BD need to address 
these issues by examining participant feedback for the therapy (66) and by considering attainment of personal goals as a 
secondary outcome to evaluate intervention utility from the patient’s perspective (67).   
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Finally, a key target for future trials should be the identification of neurobiological markers associated with cognitive 
improvement. Neuroimaging evidence indicate aberrant frontal activation as an underlying factor for cognitive impairment in BD 
(68, 69) . Meta-analyses in people with schizophrenia have associated CR interventions with enhanced frontal activations 
suggesting this might be a reliable biomarker of cognitive improvement (70, 71). Only a few studies have examined potential 
changes in neural activation following CR in people with BD, with findings supporting the model of hypofrontality and that 
modulating activity in frontal areas, particularly in the dorsolateral prefrontal cortex, potentially underlies cognitive improvement 
(72, 73). Identifying neuroimaging markers of response to CR would be an important step to establish better understanding for the 
neurobiology of declined cognition in BD and to adapt the targets of cognitive training in future interventions.
5. Conclusions
Studies considered in this review suggest that cognitive enhancement interventions may benefit cognitive and functional 
outcomes, but the evidence is far from conclusive. The association between cognitive and functional improvement is unclear, 
while the mechanisms of this transfer have not been explored. Addressing the methodological limitations of previous studies is 
necessary to evaluate the efficacy of CR and FR in a reliable and accurate way. Potential moderators of response should be 
identified in order to develop more efficient and personalized treatment programmes. 
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Table 1. Characteristics and findings of cognitive enhancing studies in bipolar disorder.
Study Design Sample
characteristics
Clinical 
characteristics
Screening for 
impairment
Outcome measures Main findings and limitations
Deckersbach 
et al., 2010
(28)
Uncontrolled 
study
CR (Ν=18)
BD: 100%
18 outpatients
Age (y): 36.8
Gender (% fem): 
55.5
Education (y):
14.5
Premorbid IQ:
105.9
BD-I (%): 82.3
Illness duration (y):
Not reported 
Mood episodes (n):
Not reported
Hospitalizations (n): 
Not reported
Current mood:
Residual symptoms
None Cognition:
RBANS, D-KEFS 
subtests (TMT, CS), 
FrSBe 
Functioning:
HPQ, LIFE-RIFT
An observer-based measure of executive dysfunction 
improved significantly post-treatment. Occupational and 
general psychosocial functioning also improved after 14 
weeks of CR. Changes in executive functioning was not 
associated with functional improvement. 
Small sample size. Uncontrolled design.
Preiss 
et al., 2013
(24)
Non-randomized
controlled trial
CT vs. SC
(N=24/21)
BD: 46.6% 
MDD: 53.4%
45 outpatients
Age (y): 42.9/45.4
Gender (% fem): 
66.7/56.3
Education (y): 
Not reported
Premorbid IQ:
BD-I (%): Not reported
Illness duration (y):
Not reported
Mood episodes (n):
Not reported
Hospitalizations (n): 
Not reported
None Cognition: 
CogniFit software 
tests
Self-report cognition: 
CFQ, DEX, EMQ
CT was associated with improvement in mood and executive 
control in a mixed sample of depressed patients. A significant 
group effect was detected in subsets of Divided Attention 
(d=0.94), Shifting (d=0.88), and Global Executive Control score 
(d=0.9). Self-report cognitive measures (DEX/CFQ) showed a 
trend for the CT group.
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          Not reported Current mood:
Depressed
Quality of life:
SQUALA
Non-randomized design. Pairwise allocation per diagnosis. 
Small sample size. High attrition rates (24-37%). No FU 
assessment.
Torrent 
et al., 2013
(29)
RCT
FR vs. PE / TAU 
(Ν=77/82/80)
BD: 100%
239 outpatients
Age (y): 
40.6/39.3/40.5
Gender (% fem): 
57.1/58.5/57.5
Education (y):
12.6/13.3/13.2
Premorbid IQ:
105.9/103.2/107.7
BD-I (%): 78/77/79
Illness duration (y):
14.8/12.7/16.4
Mood episodes (n):
11.7/9.9/13
Hospitalizations (n): 
2.8/2.6/2.5
Current mood:
Euthymic
Subjective 
criteria: 
Score ≥4 in 
FAST cognitive 
subscale 
Cognition:
VC, DSST, SS, SCWT, 
WCST, COWAT, TMT, 
ROCF, CVLT, LMS, DS, 
LNS, CPT 
Functioning:
FAST
The FR group demonstrated greater improvement over 
TAU in psychosocial functioning (FAST; d=0.3), an effect 
driven by changes in interpersonal and occupational 
functioning. Only a trend was found for the FR group 
compared to PE. Although most cognitive measures improved 
numerically, no significant differences were found between 
groups at study endpoint.
High trial attrition rate (17-29%). Unclear if ITT conducted. No 
FU assessment. Functional improvement not associated with 
cognitive gains.
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Bonnin 
et al., 2016a
(30)
Follow-up 
analysis of RCT
FR vs. PE / TAU
(Ν=54/60/58)
BD: 100%
172 outpatients
Age (y): 
40.6/39.3/40.5
Gender (% fem): 
57.1/58.5/57.5
Education (y):
12.6/13.3/13.2
Premorbid IQ:
105.9/103.2/107.7
BD-I (%):78/77/79 
Illness duration (y):
14.8/12.7/16.4
Mood episodes (n):
11.7/9.9/13
Hospitalizations (n): 
2.8/2.6/2.5
Current mood:
Euthymic
Subjective 
criteria: 
Score ≥4 in 
FAST cognitive 
subscale 
Cognition:
VC, DSST, SS, SCWT, 
WCST, COWAT, TMT, 
ROCF, CVLT, LMS, DS, 
LNS, CPT
Functioning:
FAST
A small FR group effect on FAST was maintained over TAU 
and was extended to PE at 1-year FU (d=0.18), mainly due 
to reduction of difficulties in the autonomy domain. 
An improvement in verbal memory was detected for 
the FR group only (d=0.2), and it was associated with 
functional changes.
High trial attrition rate (28-30%). No ITT analysis. 
Unblinded assessments.
Bonnin 
et al., 2016b
(31)
Subanalysis 
of RCT
FR vs. PE / TAU
(Ν=56/69/63)
BD: 100%
188 outpatients
Age (y):
40.7/39.3/39.9
Gender (% fem): 
58.9/60.9/58.7
Education (y):
12.3/12.8/12.8
Premorbid IQ:
102.8/101.7/104.8
BD-I (%): 77/73/77
Illness duration (y):
14.3/12.7/15.7
Mood episodes (n):
7/6.4/7.7
Hospitalizations (n): 
3/2.6/2.6
Current mood:
Euthymic
Objective 
criteria:
Score ≥2 SDs 
from the 
normative 
mean in one 
cognitive test 
Cognition:
VC, DSST, SS, SCWT, 
WCST, COWAT, TMT, 
ROCF, CVLT, LMS, DS, 
LNS, CPT
Functioning:
FAST
Participants with objective cognitive impairment in the FR 
group significantly improved in verbal memory compared to 
TAU (d=0.3) but not PE. A trend for improvement in verbal 
learning was detected for the FR group only. Functional 
difficulties also reduced (d=0.2) but this change was not 
associated with cognitive improvement.
No ITT analysis. No accounting for multiple comparisons. 
No FU assessment.
Sole 
et al., 2015
Subanalysis 
of RCT
53 outpatients 
Age (y): 
BD-I (%):0/0/0
Illness duration (y):
Subjective 
criteria: 
Cognition:
VC, DSST, SS, SCWT, 
In a subset of participants with bipolar type II, functional 
difficulties in the FR group reduced numerically but not 
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(32) FR vs. PE / TAU
(Ν=17/19/17)
BD: 100%
42.6/40.2/40.4
Gender (% fem): 
58.8/52.6/64.7
Education (y):
12/13.1/13.9
Premorbid IQ:
105.6/105.7/107.7
16.1/14.8/15.1
Mood episodes (n):
8.7/8.7/10.1
Hospitalizations (n): 
3/2.8/2.2
Current mood:
Euthymic
Score ≥4 in 
FAST cognitive 
subscale 
WCST, COWAT, TMT, 
ROCF, CVLT, LMS, DS, 
LNS, CPT
Functioning:
FAST
significantly over PE or TAU. A significant reduction in 
depressive symptoms was detected compared to PE only. No 
significant effects were found for any of the 
neuropsychological measures.   
Small sample size. High trial attrition rates (12-29%). 
No ITT analysis. No FU assessment.
Sanchez-
Moreno 
et al., 2017
(33)
Subanalysis 
of RCT
FR vs. PE / TAU
(Ν=33/37/29)
BD: 100%
99 outpatients
Age (y):
40.6/40.5/39
Gender (% fem): 
45.5/48.6/48.3
Education (y):
13.3/12.6/13
Premorbid IQ:
105/100.2/105.7
BD-I (%): 61/75/62
Illness duration (y):
16/11.4/14.6
Mood episodes (n):
7.5/5.1/7.5
Hospitalizations (n): 
2.6/2/2.8
Current mood:
Residual symptoms
Subjective 
criteria: 
Score ≥4 in 
FAST cognitive 
subscale 
Cognition:
VC, DSST, SS, SCWT, 
WCST, COWAT, TMT, 
ROCF, CVLT, LMS, DS, 
LNS, CPT
Functioning:
FAST
A large group effect was found for FR in psychosocial 
functioning compared to PE and TAU in a subgroup of 
participants with residual depressive symptoms (d=1.12). No 
significant effects were reported for any of the cognitive 
measures, but a trend for improvement in verbal learning and 
problem solving was detected for the FR group.  
Attrition not reported. Unclear if ITT conducted. Functional 
improvement not associated with cognitive changes.
Demant 
et al., 2015
(26)
RCT
CR vs. ST
(N=23/23)
46 outpatients
Age (y): 33.9/34
Gender (% fem): 
66.7/59.1
BD-I (%): 72.2/63.6
Illness duration (y):
Not reported
Mood episodes (n):
Subjective 
criteria: 
Score >4 
in ≥2 domains 
Cognition:
RAVLT, TMT, DSST, DS, 
LNS, COWAT, CANTAB 
(RVP, DMS, SWM, 
No significant post-treatment group effects on verbal 
learning and memory, or any other measures of cognitive or 
psychosocial functioning, were detected in participants with 
subjective cognitive complaints. An improvement for the CR 
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BD: 100% Education (y):
15.9/15.7
Premorbid IQ:
Not reported
4.9/9.2
Hospitalizations (n):
Not reported
Current mood:
Euthymic
of the CPFQ SRT), CFQ
Functioning:
FAST, CPFQ, WHOQOL, 
WSAS, EQ-5D-3L
group in verbal fluency (d=0.25) and psychological quality of 
life (WHOQOL; d=0.75) was reported at 6-month FU.
Relatively small sample size. No ITT analysis.
Low CR intensity. High attrition rate in the CR arm (21.7%).
Zyto 
et al., 2016
(25)
Uncontrolled 
study
FR (Ν=12)
BD: 100%
12 outpatients
Age (y): 50.2
Gender (% fem): 
54.5
Education (y):
4.6 in ISCED
Premorbid IQ:
109.2
BD-I (%): 100 
Illness duration (y):
28.6
Mood episodes (n): 5
Hospitalizations (n): 1.5
Current mood:
Euthymic
None Cognition:
DS, DSST, TMT, SCWT, 
RAVLT, 15-WT, RBMT, 
WCST, COWAT, CFQ
Functioning: 
FAST
 
Combined group and individual FR was feasible to deliver and 
acceptable from patients and caregivers. Psychosocial 
functioning improved, particularly the autonomy domain. 
Cognitive complaints significantly reduced at post-treatment, 
but the effect did not endure at FU. 
Small sample size. Uncontrolled design. 
Lewandowski 
et al., 2017
(23)
RCT
CR vs. CC
(N=39/36)
BD: 100%
75 outpatients
Age (y): 29.3/29.8
Gender (% fem): 
51/58
Education:
5.5/5.2 in SCID
Premorbid IQ:
BD-I (%): 100/100
Illness duration (y):
7.5/8.5
Mood episodes (n):
Not reported
Hospitalizations (n): 
4.8/3.8
None Cognition:
MCCB
Functioning:
MCAS
CR group was associated with a significant effect over 
computer control in multiple cognitive domains, including the 
composite score (d=0.8). Effect sizes were moderate to large 
(d=0.42-0.92) and remained significant at 6-month FU. These 
effects were independent to any symptom changes. Cognitive 
improvement was correlated significantly with changes in 
community functioning across the sample. 
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113.4/112.1 Current mood:
Euthymic No ITT analysis. High CR discontinuation rates (33%). 
Correlation of cognitive and functional changes was 
not specific to CR group.
Veeh 
et al., 2017
(27)
Naturalistic 
study
CR vs. TAU 
(Ν=26/10)
BD: 100%
36 outpatients
Age (y): 42.3/36.6
Gender (% fem): 
50/50
Education (y):
11.8/11.6
Premorbid IQ:
111.5/113.3
BD-I (%): 56.3/50
Illness duration (y):
Not reported
Mood episodes (n):
Not reported
Hospitalizations (n): 
Not reported
Current mood:
Euthymic
Objective 
criteria:
Score below 
the normative 
mean in two 
cognitive tests 
Cognition:
SCWT, TAP, CVLT, 
2-back, ToL, FLEI
Functioning:
SFS, WHOQOL
A significant group effect was detected for CR in measures of 
problem solving (d=0.75) and working memory (d=0.66). An 
improvement was also reported for subsyndromal depressive 
symptoms. No group differences were found in measures of 
psychosocial functioning and subjective
cognitive complaints. 
Non-randomized design. Self-selection of group allocation. 
Small sample size. Low treatment intensity. High attrition rate 
in the intervention arm. No FU assessment.
Abbreviations: Design (RCT: Randomized controlled trial; BD: Bipolar disorder; MDD: Major depressive disorder; FU: Follow-up; SD: Standard deviation; ITT: Intention-to-treat),
Interventions (CR: Cognitive remediation; CT: Cognitive training; FR: Functional remediation; PE: Psychoeducation; CC: Computer control; TAU: Treatment-as-usual; SC: Standard care; ST: 
Standard treatment), Education (SCID: Structured Clinical Interview for DSM-IV; ISCED: International Standard Classification of Education), Cognitive measures (15-WT: 15 word test; COWAT: 
Controlled oral word association test; CPT: Continuous performance test; CVLT: California verbal learning test; CS: Card sorting; DMS: Delayed matching to sample; DS: Digit span; DSST: Digit-
symbol substitution test; LMS: Logical memory scale; LNS: Letter number sequencing; MCCB: Matrics consensus cognitive battery; RAVLT: Rey-Auditory verbal learning test; RBANS: 
Repeatable battery of the assessment of neuropsychological status; RBMT: Rivermead behavioral memory test; ROCF: Rey-Osterrieth Complex Figure; RVP: Rapid visual information 
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processing; SCWT: Stroop color-word interference test; SRT: Simple reaction time; SS: Symbol search; SWM: Spatial working memory; TAP: Test of attentional performance; TMT: Trail making 
test; ToL: Tower of London; WCST: Wisconsin card sorting test; VC: Vocabulary test; ZMT: Zoo map test), Self-report cognitive measures (CFQ: Cognitive failures questionnaires; DEX: 
Dysexecutive questionnaire; EMQ: Everyday memory questionnaire; FLEI: Self-assessment test of mental ability; FrSBe: Frontal system behavior rating scale), Functional measures (CPFQ: 
Cognitive and physical functioning questionnaire; EQ-5D-3L: European quality of life – 5 dimensions – 3 levels; FAST: Functional assessment short test; HPQ: Health performance 
questionnaire; LIFE-RIFT: Longitudinal interval follow-up evaluation-Range of impaired functioning tool; MCAS: Multnomah community ability scale; SFS: Social functioning scale; SQUALA: 
Subjective quality of life questionnaires; WHOQOL: WHO Quality of life test; WSAS: Work and social adjustment scale). 
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Table 2. Description of the interventions targeting cognition and functioning in bipolar disorder. 
Study Intervention Delivery method Setting Duration Therapeutic targets Core therapy components
Deckersbach 
et al., 2010
Compensatory cognitive 
remediation
Non-computerized 
training
Individual 50 min weekly 
for 3 months & 
biweekly for 1 month 
Total: 14 sessions
Residual symptoms
Memory, Attention
Organization, Planning
Training of cognitive skills with 
adaptive level of difficulty. Strategy 
learning focused on daily life 
management. Mood monitoring.
Preiss
et al., 2013
Personalized restorative 
cognitive training
Computerized
(CogniFit)
Individual 30 min three times 
per week for 8 weeks
 
Total: 24 sessions
Multiple cognitive 
domains
Training personalized based on 
baseline evaluation. Cognitive tasks 
with adaptive level of difficulty.
Graphic and verbal feedback.
Torrent 
et al., 2013
(and all 
secondary 
analyses)
Functional remediation Pen-and-paper tasks 
and group activities
Group 90 min weekly 
for 21 weeks
Total: 21 sessions
Daily life functioning,
Memory, Attention, 
Executive functions
Psychoeducation on cognitive 
deficits and training on strategies 
to manage cognitive difficulties. 
Role-playing, group activities and 
discussions, and homework tasks to 
improve various aspects of daily-life 
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functioning.
Demant 
et al., 2015
Compensatory cognitive 
remediation 
Computerized 
(RehaCom) 
Group 120 min weekly sessions 
for 3 months
Total: 12 sessions
Attention-Concentration,
Learning-Memory 
Executive functions,
Psychosocial functioning
Psychoeducation and awareness 
of cognitive deficits. Computer 
practising and training of adaptive 
and compensatory strategies. 
Transfer of training to real-life 
activities. Mindfulness exercises. 
Zyto 
et al., 2016
Functional remediation Non-computerized 
individual training 
and group activities
Individual 
& group
90 min weekly 
for 6 weeks & 
45 min weekly 
for 6 weeks
Total: 12 sessions
Psychosocial functioning, 
Processing speed
Memory, Attention, 
Planning
Personalized goal setting and 
strategy learning to cope with 
cognitive difficulties. Gaining insight 
and challenging dysfunctional 
thoughts. Group discussions.
Lewandowski 
et al., 2017
Neuroplasticity-informed 
cognitive remediation 
(restorative) 
Computerized 
(BrainWorks)
Individual 45 min three times 
per week for 6 months
 
Total: Up to 70 sessions
Global cognition and 
community functioning
Computer practising with games 
of adaptive difficulty level based 
on user performance. Bottom-up 
training: basic sensory processing 
followed by higher level functions. 
Rewarding for correct responses.   
Veeh Compensatory cognitive Computerized Individual 90 min weekly Memory, Attention, Computer tasks with adaptive 
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et al., 2017 remediation (HappyNeuronPro) & group for 3 months
Total: 12 sessions
Problem solving, 
Planning, 
Healthy lifestyle
difficulty level. Strategy training 
with connection to daily-life tasks.  
Positive reinforcement to maintain 
motivation levels. Graphic and 
verbal feedback.
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Table 3a. Methodological evaluation of the included controlled studies using CTAM.
Study Sample 
(0-10)
Allocation 
(0-16)
Assessment 
(0-32)
Control 
(0-16)
Analysis 
(0-15)
Treatment (0-
11)
CTAM Total (0-
100)
Preiss et al., 2013 2 0 13 6 5 3 29
Torrent et al., 2013 7 10 26 16 9 6 74
Demant et al., 2015 5 13 26 6 9 6 62
Sole et al., 2015 2 10 26 16 5 6 65
Bonnin et al., 2016a 7 10 16 16 5 6 60
Bonnin et al., 2016b 7 10 26 16 5 6 70
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Lewandowski et al., 2017 7 13 26 10 9 3 71
Sanchez-Moreno et al., 2017 7 10 26 16 5 6 70
Veeh et al., 2017 2 0 26 6 5 3 42
Abbreviations: CTAM: Clinical Trials Assessment Measure.
Table 3b. Risk of bias for the included RCTs using the Cochrane Collaboration tool.
Potential sources of bias
Study
1 2 3 4 5 6 7
Global 
risk of bias 
judgement
Torrent et al., 2013 + + ? + + + No (high drop-out rate) Moderate
Demant et al., 2015 + + – + + + No (low CR retention rate; no ITT analysis) High
Sole et al., 2015 + + ? + – + No (small sample size; no ITT analysis) Moderate
Bonnin et al., 2016a + + – ? – + No (high drop-out rate; no ITT analysis) High
Bonnin et al., 2016b + + ? + – + No (no ITT analysis) Moderate
Lewandowski et al., 2017 + + ? + + + No (high drop-out rate) Moderate
Sanchez-Moreno et al., 2017 + + ? + – + No (no ITT analysis; drop-out rate not reported) Moderate
1. Selection bias: Random sequence generation; 2. Selection bias: Allocation concealment; 3. Performance bias: Blinding of participants & personnel; 
4. Detection bias: Blinding of outcome assessment; 5. Attrition bias: Adequate handling of missing data; 6. Reporting bias: Free of selective outcome reporting; 7. 
Other bias: Free of other sources of bias. +, Low risk / –, High risk / ?, Unclear risk. 
Abbreviations: BD: Bipolar disorder; ITT: Intention-to-treat analysis.
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Table 4. Categorising studies by design components potentially contributing to outcome variability.
Design 
components
Factors Factor 
levels
Number 
of studies
BD Type I & Type II 8
BD Type I only 2Diagnosis
BD Type II only 1
Euthymic 8
Residual 
depressive symptoms
2Mood symptoms 
at baseline
Depressed 1
No screening 4
Subjective screening 5
Sample 
characteristics
Baseline 
cognitive screening
Objective screening 2
Standardized battery 2Cognitive measures
Individual tests 9
Reported 1Composite score
Not reported 10
Examined 2
Assessments
Treatment feedback 
Not examined 9
Compensatory 9Approach
Restorative 2
Group 6
Individual 3Setting
Combination 2
Pen & paper 7Delivery
Computer 4
Low/long 5
Low/medium-short 4
High/short 1
Intensity/duration
High/long 1
Yes 9
Intervention
Therapist
No 2
Abbreviations: BD: Bipolar disorder. A
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Figure legends
Figure 1. PRISMA flow diagram presenting study identification and selection
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